

## Confirmed Speakers

### Keynote Speaker (Nobel Prize in Chemistry 2013)

#### KL01 - From Simulations of Biomolecules to Fighting Diseases



Prof. Martin KARPLUS  
(UNIVERSITY OF STRASBOURG, FRANCE & HARVARD UNIVERSITY, Cambridge, United States)

### Session 1: Hot Topics

#### OC04 - Quantitative Irreversible Tethering (QIT) for Covalent Ligand Discovery



Dr Gregory CRAVEN  
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

#### OC05 - Large Protein Conformational Changes in Pi3kgamma Linked to the Binding of a New Class of Highly Selective Inhibitors



Dr Göran DAHL  
(ASTRAZENECA, Mölndal, Sweden)

#### OC01 - Making Off-Rate Screening in FBDD More Amenable For Fast Dissociating Compounds



Dr Menachem GUNZBURG  
(MONASH UNIVERSITY, Parkville, Australia)

#### OC02 - Novel Active Site and Allosteric Site Binders Identified for FPPS Of T. cruzi



Ms Joy PETRICK  
(NOVARTIS, Basel, Switzerland)

#### OC03 - Dynamic Single-Molecule Approaches to Accelerate the Development of More Efficient Drugs



Dr Gerrit SITTERS  
(LUMICKS, Amsterdam, The Netherlands)

#### IL01 - Binding Kinetics and Thermodynamics in Drug Discovery



Dr Chaohong SUN  
(ABBVIE, North Chicago, United States)

### Session 2: Target Engagement

#### OC06 - Quantification of Target Occupancy in Cells and Tumor Tissue Using FCCS



Dr Frank BECKER  
(INTANA BIOSCIENCE GMBH, Planegg, Germany)

# 5th NovAliX Conference

## Confirmed Speakers

### IL03 - How to Be Selectively Promiscuous



Prof. Jack TAUNTON  
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

### IL02 - Chemical Probes for Epigenetic Targets



Prof. Masoud VEDADI  
(STRUCTURAL GENOMICS CONSORTIUM, Toronto, Canada)

## Session 3: Cryo-EM (Special Feature of the Conference)

### IL05 - Cryo-EM for Characterization and Structure Based Drug Design



Dr Bridget CARRAGHER  
(NEW YORK STRUCTURAL BIOLOGY CENTER, New York, United States)

### IL04 - How Low Can You Go? Size and Resolution Limits Using Conventional Cryo-EM



Dr Gabriel LANDER  
(THE SCRIPPS RESEARCH INSTITUTE, San Diego, United States)

### OC08 - Strength of Cryo-EM in Drug Discovery: One Could Always See Something



Dr Wen-ti LIU  
(NOVALIX, Illkirch, France)

### OC07 - Cryo-EM to Address Intractable Targets in Drug Discovery



Dr Hervé REMIGY  
(THERMO FISHER SCIENTIFIC, Eindhoven, The Netherlands)

### IL06 - Single Particle Cryo-EM Structure of the Insulin Receptor:Insulin Complex



Dr Giovanna SCAPIN  
(MERCK & CO. INC (MSD), Whitehouse Station, United States)

## Session 4: Membrane Proteins

### IL08 - Structural Insight into Allosteric Modulation of GPCRs



Dr Miles CONGREVE  
(HEPTARES, Welwyn Garden City, United Kingdom)

### IL07 - New Tools Reveal Mechanisms of Allosteric Coupling in Human GPCRs

# 5th NovAliX Conference

## Confirmed Speakers



Dr Matthew EDDY  
(UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, United States)

### OC10 - Crystal Structures of Human Glycine Receptor Alpha3 Bound to a Novel Class of Analgesic Potentiators



Dr Xin HUANG  
(AMGEN, Cambridge, United States)

### OC09 - Enabling NMR-Based Fragment Screening Using Stabilized Native GPCR: Case Study of Adenosine Receptor



Dr Anass JAWHARI  
(CALIXAR, Lyon, France)

## Session 5: Protein-Protein Interactions

### OC11 - Use of Complementary Biophysical Methods to Characterize Ligand Binding to IL-17A



Dr Parag SAHASRABUDHE  
(PFIZER, Groton, United States)

### OC12 - Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of $\alpha$ -Synuclein Aggregation in Parkinson's Disease




Ms Roxine STAATS  
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

### IL09 - Design Considerations for Synthetic Macrocycles in Drug Discovery



Prof. Adrian WHITTY  
(BOSTON UNIVERSITY, Boston, United States)

### IL10 - Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction



Dr Shilin XU  
(UNIVERSITY OF MICHIGAN, Michigan, United States)

## Session 6: Biotherapeutics

### IL13 - Emerging Higher Order Structure Techniques in Biotherapeutics Development



Dr Tapan K. DAS  
(BRISTOL-MYERS SQUIBB, New York, United States)

### IL12 - Multi-Specific Designer Proteins for Tumor Therapeutics

# 5th NovAliX Conference

## Confirmed Speakers

---



Dr Karyn T. O'NEIL  
(AR? BIOTHERAPEUTICS, Philadelphia, United States)

### **IL11 - Attacking the Cancer Cell Surface-ome with Recombinant Antibodies**



Prof. Jim WELLS  
(UCSF, San Francisco, United States)